Success Metrics

Active Trials
3(100%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

active_not_recruiting3100%

Recent Activity

3 active trials
Showing 3 of 3
active_not_recruitingphase_1

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT05441956
active_not_recruitingphase_3

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06082635
active_not_recruitingphase_2

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

NCT05955391

Clinical Trials (3)

Showing 3 of 3 trials
NCT05441956Phase 1

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

Active Not Recruiting
NCT06082635Phase 3

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Active Not Recruiting
NCT05955391Phase 2

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3